Guyasuta Investment Advisors Inc. Lowers Position in Abbott Laboratories $ABT

Guyasuta Investment Advisors Inc. decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 17.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,694 shares of the healthcare product maker’s stock after selling 4,759 shares during the period. Guyasuta Investment Advisors Inc.’s holdings in Abbott Laboratories were worth $2,059,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories in the 4th quarter valued at about $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new position in shares of Abbott Laboratories in the 4th quarter worth approximately $26,000. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Leerink Partners decreased their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. BTIG Research upped their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a research note on Wednesday, April 22nd. Piper Sandler reissued an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $118.67.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $112.92 on Wednesday. The company has a market capitalization of $195.39 billion, a P/E ratio of 36.54, a P/E/G ratio of 2.15 and a beta of 0.59. The business has a fifty day simple moving average of $98.51 and a two-hundred day simple moving average of $99.84. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the company earned $1.26 EPS. The firm’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.